Melphalan is an alkylating agent with cytotoxic action that appears to be related to the extent of its interstrand cross-linking with DNA, probably by binding at the N7 position of guanine.

Finally, the conclusion stated by Palumbo et al. 1 that melphalan 200 mg/m 2 should not be recommended for patients between the ages of 60 and 65 years is not supported by the data provided. This ...

Clinical efficiency of most therapeutic antibodies is based on their capacity to recruit and activate cytotoxic effector ... the clinic in combination with melphalan-based therapies.